Relationship between motor and non-motor symptoms in PD and other MDS

  • Research type

    Research Study

  • Full title

    Exploring the relationship between motor and non-motor symptoms in patients with Parkinson’s disease and other Movement Disorders

  • IRAS ID

    259146

  • Contact name

    Francesca Morgante

  • Contact email

    fmorgant@sgul.ac.uk

  • Sponsor organisation

    St George's University of London

  • Duration of Study in the UK

    4 years, 0 months, 1 days

  • Research summary

    Besides the well-recognized motor symptoms, movement disorders are characterized non-motor symptoms, which are often neglected and undertreated but cause major impact on quality of life. In this study we will explore the relationship between motor and non-motor symptoms in Parkinson’s disease (PD) and compare them to other two basal ganglia diseases producing movement disorders, namely Huntington’s disease (HD) and idiopathic dystonia. The primary endpoint of this study is to define the relationship between the disability determined by motor and non-motor symptoms in PD and how they affect quality of life.
    Our secondary aims are: 1) to evaluate the effect of advanced therapies (apomorphine, duodenal levodopa infusion and deep brain stimulation) on motor and non-motor symptoms in PD; 2) to compare non-motor symptoms in PD to other movement disorders (HD and idiopathic dystonia); 3) to define which non-motor symptoms contribute to quality of life in other movement disorders; 4) to assess the effect of symptomatic therapies on non-motor symptoms in other movement disorders (oral medications in HD, deep brain stimulation in idiopathic dystonia)
    To these aims, we will employ specific questionnaires routinely used in clinical practice for motor impairment, non-motor symptoms (pain, neuropsychiatric, cognitive sleep disturbances) and quality of life. We will also use psychophysical assessment and home-based monitoring of motor symptoms. We will assess PD, HD and idiopathic dystonia at baseline and at 6 months and 1-year after oral and advanced therapies, routinely used in each one of these conditions. With this study, we aim to define which are the most disabling non-motor symptoms and defining which of those may improve after therapeutic procedures routinely used in clinical practice.

  • REC name

    London - Surrey Borders Research Ethics Committee

  • REC reference

    19/LO/0411

  • Date of REC Opinion

    12 Aug 2019

  • REC opinion

    Further Information Favourable Opinion